Search Results
Aug 24, 2026, 07:00 ET Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
investigational Brainshuttle™ amyloid beta-targeting monoclonal antibody designed for enhanced brain delivery and currently being evaluated in two phase III studies in early Alzheimer's disease.Nivegacetor, an investigational, oral gamma-secretase modulator designed to reduce amyloid accumulation
More news about: Roche Diagnostics
Aug 24, 2026, 05:50 ET X Financial Reports Second Quarter 2026 Unaudited Financial Results
use in this press release the following non-GAAP financial measures: (i) adjusted net income (loss), (ii) adjusted net income (loss) per basic ADS, (iii) adjusted net income (loss) per diluted ADS, (iv) adjusted net income (loss) per basic share, and (v) adjusted net income (loss) per diluted share, each
More news about: X Financial
Aug 24, 2026, 04:06 ET First German GHG trade initiated on Argus Open Markets platform
Germany pursues increasingly ambitious transport decarbonisation targets. The country's implementation of the EU's latest Renewable Energy Directive (RED III) will increase compliance requirements and is likely to reinforce the role of THG quota reductions in achieving greenhouse gas reduction objectives.Argus
More news about: Argus Media
Aug 24, 2026, 01:30 ET PEI-Genesis Exhibits at AEDEX in New Delhi, India
company's growing manufacturing footprint across Asia. The facility provides 48-hours value-added assembly services for D38999 Series I & Series III (QPL) connectors, locally stocked inventory from leading global connector brands and offering Indian Rupees (INR) to customers in India, providing a
More news about: PEI-Genesis
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
in the 1L treatment of patients with gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) with CLDN18.2 IHC 1+ ≥ 1%; and the pivotal Phase III CLINCH‑3 study evaluating ATG-022 monotherapy for GC/GEJC patients with CLDN18.2 IHC 2+ ≥ 20%. We are confident in the potential of ATG-022 to benefit
More news about: Antengene Corporation Limited
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
inhibition where lies the potential applicability across immunologically cold solid tumors. Importantly, independent Phase III clinical studies evaluating other HDAC inhibitors in combination with immune checkpoint inhibitors have demonstrated significant synergistic efficacy
More news about: AnBogen Therapeutics
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
tumors to immune checkpoint inhibition where lies the potential applicability across immunologically cold solid tumors. Importantly, independent Phase III clinical studies evaluating other HDAC inhibitors in combination with immune checkpoint inhibitors have demonstrated significant synergistic efficacy
More news about: AnBogen Therapeutics
Aug 21, 2026, 22:00 ET Cogent Communications Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Cogent Communications Holdings, Inc. - CCOI
delivery even if timely provision was possible; (iii) as a result of (i)-(ii) above, the Company had materially misrepresented demand for its optical wavelength services and the nature of its "backlog" of wavelength orders; (iv) as a result of (i)-(iii) above, the Company was not on track to achieve its
More news about: ClaimsFiler
Aug 21, 2026, 22:00 ET Primoris Services Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Primoris Services Corporation - PRIM
overruns, and project delays across six projects; (ii) as a result, the Company's full-year 2026 Adjusted EPS and Adjusted EBITDA guidance was overstated; (iii) the Company's projected 2026 Renewables revenue was overstated; and (iv) as a result, Defendants' positive statements about the Company's business,
More news about: ClaimsFiler
Aug 21, 2026, 22:00 ET Wix.com Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Wix.com Ltd. - WIX
to those offered by other companies; (ii) the Company had understated the costs associated with developing and promoting its AI product offerings; (iii) accordingly, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and (iv) as a result, Defendants' public statements
More news about: ClaimsFiler
Aug 21, 2026, 22:00 ET PROCEPT BioRobotics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
consistently grown over time; (ii) as a result, the Company had accumulated cumulative excess field inventory of more than 10,000 handpiece units; (iii) this inventory imbalance would result in a significant sequential decline in U.S. handpiece unit sales and cause the Company to widely miss its annual
More news about: ClaimsFiler
Aug 21, 2026, 22:00 ET EquipmentShare.com Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against EquipmentShare.com Inc. - EQPT
transactions; (ii) the Company had not terminated or substantially reduced a number of the transactions with entities owned or controlled by the co-founders; (iii) as a result, the Company's financial statements were materially misleading; and (iv) as a result of the foregoing, Defendants' positive statements about
More news about: ClaimsFiler
Aug 21, 2026, 13:50 ET Datavault AI, Inc. (DVLT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Plaintiff and other Class members, as alleged herein; (ii) artificially inflate and maintain the market price of Datavault AI securities; and (iii) cause Plaintiff and other members of the Class to purchase or otherwise acquire Datavault AI securities and options at artificially inflated prices.
More news about: Law Offices of Howard G. Smith
Aug 21, 2026, 13:17 ET Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Hut 8 Corp. - HUT
Settlement as fair, reasonable, and adequate; (ii) dismiss the Action with prejudice as provided in the Stipulation of Settlement, dated June 18, 2026; (iii) approve the proposed Plan of Allocation for distribution of the proceeds of the Settlement (the "Net Settlement Fund") to Settlement Class Members;
More news about: Pomerantz LLP
Aug 21, 2026, 13:00 ET Memorial Hospital Miramar Earns Level III Maternal Levels of Care Designation from Joint Commission
Aug. 21, 2026 /PRNewswire/ -- Memorial Hospital Miramar is one of only two hospitals in South Florida that has been verified as a Level III Maternal Levels of Care designation by the Joint Commission, recognizing its ability to provide specialized care for mothers with complex medical needs
More news about: Memorial Healthcare System
Aug 21, 2026, 11:15 ET INVESTOR DEADLINE: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit Before September 28, 2026 Deadline
data for Deramiocel; (ii) the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application ("BLA"); (iii) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of
More news about: Robbins Geller Rudman & Dowd LLP
Aug 21, 2026, 10:05 ET Summary Notice to Stockholders of Spartan Acquisition Corp. II as of July 6, 2021
should be finally appointed as Class representatives for the Class and Plaintiffs' Counsel should be finally appointed as Class counsel for the Class; (iii) determine whether the Settlement and the proposed Plan of Allocation should be approved by the Court as fair, reasonable, adequate, and in the best
More news about: Levi & Korsinsky, LLP
Aug 21, 2026, 08:46 ET Global Tungsten Market Size Projected to Reach $9.62 Billion By 2030
tonnes of WO₃ in concentrate per year over an initial eight-year mine life.The study is supported by a US$6.2 million Defense Production Act Title III investment awarded to the Company's U.S. subsidiary, and Guardian has targeted submission of a mine Plan of Operations to the Bureau of Land Management
More news about: USA News Group
Aug 21, 2026, 08:42 ET Munley Law Lawyers Named to 2027 Best Lawyers in America® List
Personal Injury Litigation - Plaintiffs, Product Liability Litigation - Plaintiffs, and Workers' Compensation Law - ClaimantsRobert W. Munley III - Personal Injury Litigation - Plaintiffs, Product Liability Litigation - Plaintiffs, and Workers' Compensation - ClaimantsJohn M. Mulcahey -
More news about: Munley Law
Aug 21, 2026, 08:00 ET Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
safety data and topline results for the Phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) our provision of initial safety data and topline results for the Phase 1/2 clinical trial for our ATR-04 program, (iv) statements about our clinical
More news about: Azitra, Inc.
Aug 21, 2026, 07:50 ET DVLT Investors Have Opportunity to Lead Datavault AI Inc. Securities Fraud Lawsuit
overstated the volume of trading activity on the Datavault Platform, which was in fact minimal; (3) Datavault's undisclosed connections with Edward Withrow III, a convicted felon, when revealed, would cause Datavault AI to incur reputational harm; and (4) as a result, defendants' public statements
More news about: THE ROSEN LAW FIRM, P. A.
Aug 21, 2026, 05:13 ET Keymed Biosciences Announces 2026 H1 Results and Business Updates
penetration into county-level and primary care markets. Pipeline Momentum: Stapokibart's NDA for adolescent AD and prurigo nodularis were accepted; Phase III trials in pediatric AD and adolescent SAR are ongoing.CM336 (BCMA x CD3 bispecific antibody), on June 5, NewCo partner Ouro
More news about: Keymed Biosciences
Aug 21, 2026, 04:39 ET Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN
According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression its Phase III Fianlimab-Libtayo Study showed signs of success and minimized risks presented by the study. The Company's study ultimately failed to achieve its primary
More news about: DJS Law Group LLP
Aug 21, 2026, 03:24 ET 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
leading R&D in China.Yisaituo® (amdokitug injection): Patient enrollment completed for the Phase III trial in ankylosing spondylitis; first patient enrolled in the Phase III trial for non-radiographic axial spondyloarthritis.Yisaina® (anflekitug injection): Dose-exploration
More news about: 3SBio Inc.
Aug 20, 2026, 20:00 ET Sunshine Guojian Releases 2026 Interim Report:
continues to advance Phase III clinical trials for multiple products. Amdokitug Injection (R&D code: 608): Enrollment of all subjects in the Phase III clinical trial for ankylosing spondylitis has been completed. The first subject has been enrolled in the Phase III clinical trial for non-radiographic
More news about: 3SBio Inc.